Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ramucirumab”

146 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 146 results

Early research (Phase 1)Ended earlyNCT00428272
What this trial is testing

HGS-ETR2 to Treat Children With Solid Tumors

Who this might be right for
Ewing's SarcomaOsteosarcomaNeuroblastoma+1 more
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)WithdrawnNCT03766607
What this trial is testing

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Korean South West Oncology Group
Large-scale testing (Phase 3)Looking for participantsNCT06203600
What this trial is testing

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Who this might be right for
Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma+13 more
National Cancer Institute (NCI) 224
Testing effectiveness (Phase 2)Study completedNCT02999295
What this trial is testing

Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Region (GEJ) Cancer
National Cancer Center, Japan 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06564298
What this trial is testing

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Who this might be right for
Stomach Neoplasms
The First Affiliated Hospital with Nanjing Medical University 39
Early research (Phase 1)Ended earlyNCT03863587
What this trial is testing

Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects

Who this might be right for
Healthy Male Volunteers
Shanghai Henlius Biotech 24
Early research (Phase 1)Ended earlyNCT04557384
What this trial is testing

Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Who this might be right for
Advanced Solid Tumor
Eli Lilly and Company 3
Large-scale testing (Phase 3)Study completedNCT03520946
What this trial is testing

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 430
Testing effectiveness (Phase 2)Study completedNCT03745430
What this trial is testing

RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Adenocarcinoma
Hellenic Cooperative Oncology Group 54
Testing effectiveness (Phase 2)Looking for participantsNCT04660760
What this trial is testing

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+28 more
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Study completedNCT02443883
What this trial is testing

Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 164
Testing effectiveness (Phase 2)Ended earlyNCT05062980
What this trial is testing

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Genprex, Inc. 5
Large-scale testing (Phase 3)UnknownNCT02934464
What this trial is testing

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Who this might be right for
Stomach Neoplasms
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 280
Testing effectiveness (Phase 2)Ended earlyNCT05071053
What this trial is testing

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer

Who this might be right for
Adenocarcinoma GastricGastrooesophageal Cancer
Sanofi 35
Testing effectiveness (Phase 2)Study completedNCT03971474
What this trial is testing

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
SWOG Cancer Research Network 166
Testing effectiveness (Phase 2)Study completedNCT00895180
What this trial is testing

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Who this might be right for
Adult Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 80
Early research (Phase 1)Study completedNCT04495478
What this trial is testing

Ramucirumab (LY3009806) in Healthy Participants

Who this might be right for
Healthy
Eli Lilly and Company 50
Large-scale testing (Phase 3)Study completedNCT00917384
What this trial is testing

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Who this might be right for
Gastric CancerAdenocarcinoma
Eli Lilly and Company 355
Testing effectiveness (Phase 2)Study completedNCT02628951
What this trial is testing

Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Samsung Medical Center 62
Large-scale testing (Phase 3)Study completedNCT01168973
What this trial is testing

Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 1,253
Load More Results
116